Bibliographic Details
| Title: |
Prelamin A and lamin A appear to be dispensable in the nuclear lamina. |
| Authors: |
Fong, Loren G.1, Ng, Jennifer K.2, Lammerding, Jan3, Vickers, Timothy A.4, Meta, Margarita5, Coté, Nathan2, Gavino, Bryant2, Xin Qiao1, Chang, Sandy Y.1, Young, Stephanie R.1, Yang, Shao H.1, Stewart, Colin L.6, Lee, Richard T.3, Bennett, C. Frank4, Bergo, Martin O.7, Young, Stephen G.1 sgyoung@mednet.ucla.edu, Coté, Nathan (AUTHOR), Qiao, Xin (AUTHOR) |
| Source: |
Journal of Clinical Investigation. Mar2006, Vol. 116 Issue 3, p743-752. 10p. 3 Color Photographs, 5 Black and White Photographs, 1 Diagram, 6 Graphs. |
| Subject Terms: |
*NUCLEAR membranes, *CELL nuclei, *OLIGONUCLEOTIDES, *TRANSCRIPTION factors, *PROGERIA, *PHENOTYPES |
| Abstract: |
Lamin A and lamin C, both products of Lmna, are key components of the nuclear lamina. In the mouse, a deficiency in both lamin A and lamin C leads to slow growth, muscle weakness, and death by 6 weeks of age. Fibroblasts deficient in lamins A and C contain misshapen and structurally weakened nuclei, and emerin is mislocalized away from the nuclear envelope. The physiologic rationale for the existence of the 2 different Lmna products lamin A and lamin C is unclear, although several reports have suggested that lamin A may have particularly important functions, for example in the targeting of emerin and lamin C to the nuclear envelope. Here we report the development of lamin C-only mice (Lmna(LCO/LCO)), which produce lamin C but no lamin A or prelamin A (the precursor to lamin A). Lmna(LCO/LCO) mice were entirely healthy, and Lmna(LCO/LCO) cells displayed normal emerin targeting and exhibited only very minimal alterations in nuclear shape and nuclear deformability. Thus, at least in the mouse, prelamin A and lamin A appear to be dispensable. Nevertheless, an accumulation of farnesyl-prelamin A (as occurs with a deficiency in the prelamin A processing enzyme Zmpste24) caused dramatically misshapen nuclei and progeria-like disease phenotypes. The apparent dispensability of prelamin A suggested that lamin A-related progeroid syndromes might be treated with impunity by reducing prelamin A synthesis. Remarkably, the presence of a single Lmna(LCO) allele eliminated the nuclear shape abnormalities and progeria-like disease phenotypes in Zmpste24-/- mice. Moreover, treating Zmpste24-/- cells with a prelamin A-specific antisense oligonucleotide reduced prelamin A levels and significantly reduced the frequency of misshapen nuclei. These studies suggest a new therapeutic strategy for treating progeria and other lamin A diseases. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Clinical Investigation is the property of American Society for Clinical Investigation and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
